A detailed history of North Crest Asset Manangement, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, North Crest Asset Manangement, LLC holds 51,150 shares of CTKB stock, worth $286,440. This represents 0.01% of its overall portfolio holdings.

Number of Shares
51,150
Previous 52,050 1.73%
Holding current value
$286,440
Previous $474,000 27.64%
% of portfolio
0.01%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$6.29 - $9.15 $5,661 - $8,235
-900 Reduced 1.73%
51,150 $343,000
Q3 2023

Nov 13, 2023

SELL
$5.52 - $9.5 $5,520 - $9,500
-1,000 Reduced 1.89%
52,050 $287,000
Q1 2023

Apr 25, 2023

BUY
$8.44 - $13.47 $8,440 - $13,470
1,000 Added 1.92%
53,050 $487,000
Q4 2022

Feb 01, 2023

BUY
$9.71 - $15.86 $505,405 - $825,513
52,050 New
52,050 $531,000

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $754M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track North Crest Asset Manangement, LLC Portfolio

Follow North Crest Asset Manangement, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of North Crest Asset Manangement, LLC, based on Form 13F filings with the SEC.

News

Stay updated on North Crest Asset Manangement, LLC with notifications on news.